Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
59.89
87.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Shenzhen New Industries Biomedical Engineering Co Ltd
Shenzhen New Industries Biomedical Engineering Co Ltd
Accrued Liabilities
Shenzhen New Industries Biomedical Engineering Co Ltd
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Accrued Liabilities
¥185m
|
CAGR 3-Years
18%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eyebright Medical Technology Beijing Co Ltd
SSE:688050
|
Accrued Liabilities
¥51.3m
|
CAGR 3-Years
42%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
S
|
Shandong Pharmaceutical Glass Co Ltd
SSE:600529
|
Accrued Liabilities
¥93.5m
|
CAGR 3-Years
36%
|
CAGR 5-Years
11%
|
CAGR 10-Years
26%
|
|
|
Autobio Diagnostics Co Ltd
SSE:603658
|
Accrued Liabilities
¥108.2m
|
CAGR 3-Years
33%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Winner Medical Co Ltd
SZSE:300888
|
Accrued Liabilities
¥478.1m
|
CAGR 3-Years
19%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
Glance View
Amidst the sprawling innovation-centric landscape of Shenzhen, Shenzhen New Industries Biomedical Engineering Co., Ltd., often abbreviated as SNIBE, stands out as a beacon in the realm of biotechnology. Founded in 1995, SNIBE has steadily carved out a significant niche in the medical devices industry, particularly in in-vitro diagnostic products. The company has become synonymous with the development, manufacture, and sale of diagnostic reagents and fully automated chemiluminescence immunoassay systems, which have gained widespread recognition in over 150 countries. By focusing on the integration of cutting-edge technology in diagnostic immunoassays, SNIBE ensures that hospitals and laboratories worldwide can attain high accuracy and efficiency in medical testing, while concurrently meeting the growing global demand for advanced diagnostic tools. The financial engine that propels SNIBE is powered by its robust supply chain and diversified product offerings. With its line-up of innovative diagnostic products, the company generates the bulk of its revenue through long-term contracts with health institutions, research centers, and clinical laboratories. These partnerships are augmented by continuous investment in research and development, ensuring a steady flow of novel products capable of addressing pressing medical needs. Additionally, SNIBE’s strategic emphasis on international markets has fortified its revenue streams, allowing it to mitigate risks associated with saturation or volatility in domestic markets. Through its unwavering focus on innovation and strategic expansion, SNIBE not only sustains its financial health but also continually contributes to advancements in global healthcare diagnostics.
See Also
What is Shenzhen New Industries Biomedical Engineering Co Ltd's Accrued Liabilities?
Accrued Liabilities
185m
CNY
Based on the financial report for Dec 31, 2023, Shenzhen New Industries Biomedical Engineering Co Ltd's Accrued Liabilities amounts to 185m CNY.
What is Shenzhen New Industries Biomedical Engineering Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
22%
Over the last year, the Accrued Liabilities growth was 23%. The average annual Accrued Liabilities growth rates for Shenzhen New Industries Biomedical Engineering Co Ltd have been 18% over the past three years , 22% over the past five years .
You don't have any saved screeners yet